IDflu
influenza vaccine (split virion, inactivated)
Table of contents
Overview
The marketing authorisation for IDflu has been withdrawn at the request of the marketing authorisation holder.
Authorisation details
| Product details | |
|---|---|
| Name |
IDflu
|
| Agency product number |
EMEA/H/C/000966
|
| Active substance |
influenza virus (inactivated, split) of the following strains:A/California/7/2009 (H1N1)pdm09 - like strain (A/California/7/2009, NYMC X-179A)A/Hong Kong/4801/2014 (H3N2) - like strain (A/Hong Kong/4801/2014, NYMC X-263B)B/Brisbane/60/2008 - like strain (B/Brisbane/60/2008, wild type)
|
| International non-proprietary name (INN) or common name |
influenza vaccine (split virion, inactivated)
|
| Therapeutic area (MeSH) |
|
| Anatomical therapeutic chemical (ATC) code |
J07BB02
|
| Publication details | |
|---|---|
| Marketing-authorisation holder |
Sanofi Pasteur S.A.
|
| Revision |
13
|
| Date of issue of marketing authorisation valid throughout the European Union |
24/02/2009
|
| Contact address |
2, avenue Pont Pasteur
F-69007 Lyon France |
Product information
03/01/2017 IDflu - EMEA/H/C/000966 - N/0048
This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.
Pharmacotherapeutic group
Vaccines
Therapeutic indication
Prophylaxis of influenza in individuals 60 years of age and over, especially in those who run an increased risk of associated complications.
The use of IDflu should be based on official recommendations.